CN1537613A - Novel concentrated pill of wuji-Baifeng contg. black-bone chicken - Google Patents
Novel concentrated pill of wuji-Baifeng contg. black-bone chicken Download PDFInfo
- Publication number
- CN1537613A CN1537613A CNA2003101018729A CN200310101872A CN1537613A CN 1537613 A CN1537613 A CN 1537613A CN A2003101018729 A CNA2003101018729 A CN A2003101018729A CN 200310101872 A CN200310101872 A CN 200310101872A CN 1537613 A CN1537613 A CN 1537613A
- Authority
- CN
- China
- Prior art keywords
- radix
- technology
- volatile oil
- rhizoma
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006187 pill Substances 0.000 title claims abstract description 65
- 241000287828 Gallus gallus Species 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 51
- 239000012528 membrane Substances 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000005516 engineering process Methods 0.000 claims description 117
- 239000003814 drug Substances 0.000 claims description 46
- 239000000341 volatile oil Substances 0.000 claims description 46
- 239000000843 powder Substances 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 241000209020 Cornus Species 0.000 claims description 41
- 229940079593 drug Drugs 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 29
- 210000000582 semen Anatomy 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 26
- 241001550206 Colla Species 0.000 claims description 22
- 241000208340 Araliaceae Species 0.000 claims description 21
- 244000268590 Euryale ferox Species 0.000 claims description 21
- 235000006487 Euryale ferox Nutrition 0.000 claims description 21
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 21
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 21
- 235000008434 ginseng Nutrition 0.000 claims description 21
- 239000003094 microcapsule Substances 0.000 claims description 21
- 239000009636 Huang Qi Substances 0.000 claims description 20
- 238000004108 freeze drying Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000012567 medical material Substances 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 11
- 238000004821 distillation Methods 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 9
- 239000008188 pellet Substances 0.000 claims description 9
- 238000005498 polishing Methods 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 9
- 235000013311 vegetables Nutrition 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 239000011812 mixed powder Substances 0.000 claims description 6
- 235000010489 acacia gum Nutrition 0.000 claims description 5
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 238000005360 mashing Methods 0.000 claims description 4
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims 4
- 238000000926 separation method Methods 0.000 abstract description 3
- 238000010298 pulverizing process Methods 0.000 abstract description 2
- 241000233805 Phoenix Species 0.000 abstract 1
- 238000007723 die pressing method Methods 0.000 abstract 1
- 238000001746 injection moulding Methods 0.000 abstract 1
- 230000008569 process Effects 0.000 description 41
- 241000699670 Mus sp. Species 0.000 description 36
- 230000000694 effects Effects 0.000 description 32
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 18
- 229960004397 cyclophosphamide Drugs 0.000 description 18
- 208000032843 Hemorrhage Diseases 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 208000034158 bleeding Diseases 0.000 description 11
- 230000000740 bleeding effect Effects 0.000 description 11
- 239000000052 vinegar Substances 0.000 description 11
- 235000021419 vinegar Nutrition 0.000 description 11
- 210000000078 claw Anatomy 0.000 description 9
- 210000003746 feather Anatomy 0.000 description 9
- 238000005242 forging Methods 0.000 description 9
- 210000000936 intestine Anatomy 0.000 description 9
- 210000002460 smooth muscle Anatomy 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 239000009557 Bak Foong Pill Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 210000004100 adrenal gland Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 210000001541 thymus gland Anatomy 0.000 description 7
- 206010013935 Dysmenorrhoea Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000010025 steaming Methods 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000002180 anti-stress Effects 0.000 description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 201000005630 leukorrhea Diseases 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 210000004908 prostatic fluid Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- -1 micropowder Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000003191 uterotonic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A white phoenix condensed pill of black-bone chicken is prepared by membrane separation technique, freezy drying technique, superfine pulverizing technique, and die-pressing or injection moulding. Its active components in condensed pill is increased by 3-4 times.
Description
Technical field:
The present invention relates to a kind of new WUJI BAIFENG concentrated pill, its prescription and preparation technology, membrane separation technique, Freeze Drying Technique, superfine communication technique have particularly been adopted, adopt pressing or mould process such as method for making, make its crude drug amount that in the 1000g pill, is comprised bring up to original 3-4 doubly.
Background technology:
WUJI BAIFENG WAN comes from " Longevity and Life Preservation " of Ming Dynasty Gong Yun woods, and 2000 editions one one of Chinese Pharmacopoeias have recorded this kind.Full side forms with Gallus Domesticus (removing feather claw and intestine), Radix Ginseng, Colla cornus cervi, Concha Ostreae (forging), the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Glycyrrhizae, the Radix Astragali, Carapax Trionycis (system), Rhizoma Cyperi (vinegar system), Radix Asparagi, Ootheca Mantidis, Radix Rehmanniae Preparata, the Radix Rehmanniae, Rhizoma Chuanxiong, Cornu Cervi Degelatinatum, Radix Stellariae, Semen Euryales (stir-fry), Rhizoma Dioscoreae, Radix Salviae Miltiorrhizae, has the merit of benefiting qi and nourishing blood, adjusting meridian and stopping leukorrhea.Be used for QI and blood deficiency, asthenic body, soreness of the waist and knees, menoxenia, bleeding not during menses is traditional gynecological's good medicine.
And the WUJI BAIFENG concentrated pill prescription of common process preparation is Gallus Domesticus (removing feather claw and intestine) 640g, Radix Ginseng 128g, Colla cornus cervi 128g, Concha Ostreae (forging) 48g, Radix Paeoniae Alba 128g, Radix Angelicae Sinensis 144g, Radix Glycyrrhizae 32g, Radix Astragali 32g, Carapax Trionycis (system) 64g, Rhizoma Cyperi (vinegar system) 128g, Radix Asparagi 64g, Ootheca Mantidis 48g, Radix Rehmanniae Preparata 256g, Radix Rehmanniae 256g, Rhizoma Chuanxiong 64g, Cornu Cervi Degelatinatum 48g, Radix Stellariae 26g, Semen Euryales (stir-fry) 64g, Rhizoma Dioscoreae 128g, Radix Salviae Miltiorrhizae 128g, preparation technology is: get the Radix Astragali, Radix Angelicae Sinensis, Rhizoma Chuanxiong, the Radix Paeoniae Alba, put in the jar together with Gallus Domesticus, add yellow wine 2000g, covered and enclosed, steam after Gallus Domesticus rots and pull out, chicken soup is concentrated in right amount, admixes Ootheca Mantidis, dry back and Rhizoma Cyperi together with above-mentioned medicine, Semen Euryales, Rhizoma Dioscoreae, Radix Stellariae, Carapax Trionycis, Cornu Cervi Degelatinatum, Radix Ginseng, special oyster, Radix Glycyrrhizae, Radix Salviae Miltiorrhizae, and Colla cornus cervi (get Colla cornus cervi 84g system Colla cornus cervi pearl) to make fine powder altogether standby; Get Radix Rehmanniae, Radix Rehmanniae Preparata, Radix Asparagi and decoct with water secondary, each 2 hours, collecting decoction, get the clear paste that supernatant concentration to relative density is 1.25-1.30 (65 ℃) after the placement, and will add mixing after the Colla cornus cervi 44g molten, and getting concentrated solution, above-mentioned medicated powder is with concentrating the liquid flooding ball, drying promptly gets the concentrated pill of 1000g.The concentrated pill dose of this prepared big (9g, once-a-day), absorb slow, taste is not good.We remove impurity a large amount of in the medical material by adopting membrane separation technique, reduce the taking dose of WUJI BAIFENG WAN, reduce poisonous side effect of medicine, improve mouthfeel; By using Freeze Drying Technique, improve the difficult physical property of pulverizing medical material, make it be easy to pulverize; By the utilization superfine communication technique, improve some pharmacological action index of WUJI BAIFENG WAN.WUJI BAIFENG WAN clinical efficacy through above-mentioned process modification preparation increases, and side effect reduces.
Summary of the invention:
The invention provides a kind of new WUJI BAIFENG WAN prescription, it is as follows to fill a prescription:
Gallus Domesticus (removing feather claw and intestine) 1920g-2560g, Radix Ginseng 384g-512g, Colla cornus cervi 384g-512g, Concha Ostreae (forging) 144g-192g, Radix Paeoniae Alba 384g-512g, Radix Angelicae Sinensis 432g-576g, Radix Glycyrrhizae 96g-128g, Radix Astragali 96g-128g, Carapax Trionycis (system) 192g-256g, Rhizoma Cyperi (vinegar system) 384g-512g, Radix Asparagi 192g-256g, Ootheca Mantidis 144g-192g, Radix Rehmanniae Preparata 768g-1024g, Radix Rehmanniae 768g-1024g, Rhizoma Chuanxiong 192g-256g, Cornu Cervi Degelatinatum 144g-192g, Radix Stellariae 78g-104g, Semen Euryales (stir-fry) 192g-256g, Rhizoma Dioscoreae 384g-512g, Radix Salviae Miltiorrhizae 384g-512g, preferably:
Gallus Domesticus (removing feather claw and intestine) 1920g, Radix Ginseng 384g, Colla cornus cervi 384g, Concha Ostreae (forging) 144g, Radix Paeoniae Alba 384g, Radix Angelicae Sinensis 432g, Radix Glycyrrhizae 96g, Radix Astragali 96g, Carapax Trionycis (system) 192g, Rhizoma Cyperi (vinegar system) 384g, Radix Asparagi 192g, Ootheca Mantidis 144g, Radix Rehmanniae Preparata 768g, Radix Rehmanniae 768g, Rhizoma Chuanxiong 192g, Cornu Cervi Degelatinatum 144g, Radix Stellariae 78g, Semen Euryales (stir-fry) 192g, Rhizoma Dioscoreae 384g, Radix Salviae Miltiorrhizae 384g
And,
Gallus Domesticus (removing feather claw and intestine) 2560g, Radix Ginseng 512g, Colla cornus cervi 512g, Concha Ostreae (forging) 192g, Radix Paeoniae Alba 512g, Radix Angelicae Sinensis 576g, Radix Glycyrrhizae 128g, Radix Astragali 128g, Carapax Trionycis (system) 256g, Rhizoma Cyperi (vinegar system) 512g, Radix Asparagi 256g, Ootheca Mantidis 192g, Radix Rehmanniae Preparata 1024g, Radix Rehmanniae 1024g, Rhizoma Chuanxiong 256g, Cornu Cervi Degelatinatum 192g, Radix Stellariae 104g, Semen Euryales (stir-fry) 256g, Rhizoma Dioscoreae 512g, Radix Salviae Miltiorrhizae 512g,
More than in the prescription, the amount of medicine is calculated with the crude drug amount, and above-mentioned amount can be prepared into the concentrated pill preparation of the present invention about 1000g.
More than measure medical material, when carrying out large-scale production, can increase their amount, but the constant rate between them, for especial patient, can suitably increase or reduce wherein the amount of certain or some medical materials, adapting to these patients' needs, but the amount that increases or reduce is as the criterion with the characteristic functions that still has prescription, generally is no more than a times of above-mentioned amount.
The present invention also provides the preparation method with above formulation WUJI BAIFENG concentrated pill, may further comprise the steps:
A, contain volatile oil in will writing out a prescription vegetable drug (Radix Angelicae Sinensis, Rhizoma Cyperi, Rhizoma Chuanxiong) through water vapour distillation volatile oil, extract the above-mentioned medical material behind the volatile oil of back, incorporate step b into and extract again;
B, with Radix Ginseng, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Glycyrrhizae, the Radix Astragali, Rhizoma Cyperi (vinegar system), Radix Asparagi, Radix Rehmanniae Preparata, Radix Rehmanniae, Rhizoma Chuanxiong, Radix Stellariae, Radix Salviae Miltiorrhizae, water or alcohol extraction effective ingredient, gained extracting solution concentrate, concentrated solution gets dry powder through lyophilization;
C, will write out a prescription in Gallus Domesticus (removing feather claw and intestine), Colla cornus cervi, Concha Ostreae (forging) Carapax Trionycis (system), Ootheca Mantidis, Cornu Cervi Degelatinatum through the wine processing evaporate to dryness, mix with Rhizoma Dioscoreae, Semen Euryales coarse powder, after lyophilization, get micropowder through micronizing again;
D, with volatile oil, be the capsule material with natural macromolecular material, be prepared into microcapsule through the microencapsulation technology, washing is made the microcapsule powder after the cold drying, or volatile oil do not make dry microcapsule powder, and is stand-by;
E, dry powder, the micropowder of step c, the microcapsule powder mix homogeneously of steps d with step b, mixed powder, or with the dry powder of step b, the micropowder mix homogeneously of step c, the stand-by volatile oil of steps d is sprayed into, airtight a period of time, mixed powder;
F, the mixed powder of step e is pressed into ball with pellet press, dry, polishing promptly gets the concentrated pill finished product.Above step can be divided into two kinds of technologies, technology A and technology B, and technology A wherein is as follows:
1, contains the vegetable drug (Radix Angelicae Sinensis, Rhizoma Cyperi, Rhizoma Chuanxiong) of volatile oil behind water vapour distillation volatile oil in will writing out a prescription, again with 12 flavor plant medicine materials such as Radix Ginseng, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Glycyrrhizae, the Radix Astragali, Rhizoma Cyperi (vinegar system), Radix Asparagi, Radix Rehmanniae Preparata, Radix Rehmanniae, Rhizoma Chuanxiong, Radix Stellariae, Radix Salviae Miltiorrhizae, effective component extracting, the gained extracting solution gets concentrated solution after NF membrane concentrates, get dry powder through lyophilization again.
2, will write out a prescription in Six-element animal medicinal material such as Gallus Domesticus (removing feather claw and intestine), Colla cornus cervi, Concha Ostreae (forging) Carapax Trionycis (system), Ootheca Mantidis, Cornu Cervi Degelatinatum through the wine processing evaporate to dryness, mix with Rhizoma Dioscoreae, Semen Euryales coarse powder, after lyophilization, get micropowder through micronizing again;
3, the volatile oil that other is carried is the capsule material with natural macromolecular material, is prepared into microcapsule through the microencapsulation technology, gets the microcapsule powder after the washing cold drying;
4, with dry powder, micropowder, microcapsule powder mix homogeneously, be pressed into ball with pellet press, dry, polishing promptly gets the concentrated pill finished product.
Technology B is as follows:
1, contains the vegetable drug (Radix Angelicae Sinensis, Rhizoma Cyperi, Rhizoma Chuanxiong) of volatile oil behind water vapour distillation volatile oil in will writing out a prescription, plant medicine materials (except Rhizoma Dioscoreae, the Semen Euryales) such as Radix Ginseng, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Glycyrrhizae, the Radix Astragali, Rhizoma Cyperi (vinegar system), Radix Asparagi, Radix Rehmanniae Preparata, Radix Rehmanniae, Rhizoma Chuanxiong, Radix Stellariae, Radix Salviae Miltiorrhizae, effective component extracting, the gained extracting solution gets concentrated solution after NF membrane concentrates, get dry powder through lyophilization again;
2, will write out a prescription in animal medicinal material behind the wine processing evaporate to dryness, mix with Rhizoma Dioscoreae, Semen Euryales coarse powder, after lyophilization, get micropowder through micronizing again;
3, with above micropowder, dry powder mixing, the volatile oil that other is carried sprays into, airtight 2-6 hour;
4, use the pellet processing machine pill, dry, polishing promptly get the concentrated pill finished product.
Above extraction step can adopt water to carry or alcohol extraction, also can adopt water extract-alcohol precipitation or alcohol extracting-water precipitating, the ethanol that described alcohol is preferably pharmaceutical, and concentration can be 30%-100%.Described natural macromolecular material is gelatin, arabic gum.Described microencapsulation technology, it is routine techniques, can adopt following technology, carrying volatile oil and 4% gumwater (volume ratio is 1: 25) are poured in the tissue mashing machine, and high-speed stirred made volatile oil emulsion in 1 minute, and 4% gelatin solution (with the arabic gum equivalent volumes) is mixed with emulsion, stirred 10 minutes, put in 37 ℃ of water-baths, constantly stir, it is an amount of to drip 10% acetum.Transferring pH value is 4, adds 200 milliliters of dilutions of acidify distilled water (pH value 4.5), constantly stirs and is cooled to 25 ℃, puts to be cooled in the ice bath below 10 ℃ again, adds 37% formaldehyde, and to transfer pH value with 20% sodium hydroxide be 8-9, continues stirring 1 hour.Leave standstill, the supernatant that inclines, microcapsule is washed till formaldehydeless flavor with distilled water, and cold drying promptly gets volatile oil microcapsule powder.Described micronizing can adopt the fluid energy mill micronizing, and the micropowder granularity of gained is 3-20 μ m.
Preparation of the present invention is the 1/3-1/4 of the old preparation taking dose that has gone on the market, and reduces dose greatly, conveniently takes.The present invention collects the volatile oil component of raw medicinal material, better utilization the effective ingredient of raw medicinal material, guarantee curative effect of medication, water is carried or alcohol extracting method and concentrate invalid macromole organic impuritiess such as the cellulose can remove wherein, protein, pectin, natural gum through NF membrane, can reduce side effect, strengthen clinical use curative effect.
Beneficial effect of the present invention below is described by experiment.
The pharmacological effect comparative experiments
We have carried out following comparative study to pharmacological effects such as the benefiting qi and nourishing blood of three kinds of preparations of WUJI BAIFENG WAN (concentrated pill) embodiment 1 (technology A), embodiment 2 (technology B), old common process, regulating menstruation, hemostasis and the effect of toxicity aspect.
Material and method
1.1 experiment material
1.1.1 animal Kunming kind healthy mice, body weight 18-22g, male female half and half, random packet is provided by Jiangxi Medical College's Experimental Animal Center, quality certification 021-9601.The Wistar rat, body weight 200-250g, male female half and half, random packet is provided by Jiangxi Medical College's Experimental Animal Center, quality certification 021-9602.
1.1.2 medicine
WUJI BAIFENG WAN (concentrated pill) embodiment 1 (technology A), embodiment 2 (technology B) and common process concentrated pill etc. are bought by Huiren Group Co., Ltd, take by weighing a certain amount ofly before the experiment, are dissolved in water to desired concn, and refrigerator is preserved, and uses for experiment.
Cyclophosphamide for injection: 0.2g * 5 bottle, adult 0.2g, once a day, the permanent auspicious medical limited company in Jiangxi, lot number: 01092821.Get 1 bottle of cyclophosphamide (200mg), add the injection water to 50ml, now with the current; Dou Shi reagent: sodium bicarbonate 1.0g, potassium cyanide 0.05g high-potassium ferricyanide 0.2g, distilled water 1000ml surveys hemoglobin and uses.
1.1.3 key instrument, electronic stopclock, wrist-watch three factories in Shanghai produce; 721 spectrophotometers, analytical tool factory in Shanghai produces; Optical microscope, Japan produces (Olympus).
1.2 experimental technique and result
1.2.1 influence to acute bleeding mice model of blood dificiency
Get white mice, Hb value (cyanmethemoglobin algoscopy) and RBC number (optical microscopy) [2] are measured in Mus tail blood sampling immediately, after with in 37 ℃ of left and right sides warm water of Mus tail wound immersion, the about 0.5ml of blood-letting causes the acute bleeding model of blood dificiency.In losing blood back 24 hours, Hb and RBC value are measured in the blood sampling of Mus tail, the difference gastric infusion, and continuous 7 days, every day 1 time, Hb and RBC were measured in Mus tail blood sampling in 24 hours after the last administration.The result shows that the back white mice Hb that loses blood, RBC value all significantly are lower than the preceding (P＜0.01=that loses blood.WUJI BAIFENG concentrated pill technology A, technology B and common process group all can significantly promote the lose blood Hb of white mice and the recovery (P＜0.05=of RBC value.Effect between each preparation roughly the same.Concrete outcome sees Table 1,2.
Table 1 WUJI BAIFENG concentrated pills etc. are to the influence (g%) of acute bleeding model of blood dificiency mice Hb
Dosage
After treating after losing blood before group number of animals g crude drug/kg loses blood
Blank group 16-10.32 ± 1.75 7.71 ± 0.93 8.29 ± 1.04
Common process 14 18.0 9.85 ± 1.07 7.49 ± 1.04 9.83 ± 1.57
▲
Technology A low dosage 15 9.0 10.46 ± 1.63 7.75 ± 0.99 9.92 ± 1.33
▲
Technology A high dose 16 18.0 9.72 ± 1.84 7.33 ± 0.89 9.81 ± 1.31
▲
Technology B low dosage 15 9.0 9.89 ± 1.56 7.23 ± 0.92 9.78 ± 1.22
▲
Technology B high dose 14 18.0 10.21 ± 1.38 7.50 ± 0.61 9.97 ± 1.06
▲
Compare with blank (giving normal saline) matched group,
▲P＜0.05,
▲ ▲P＜0.01.Down together.
Table 2 WUJI BAIFENG concentrated pills etc. are to the influence (* 10 of acute bleeding model of blood dificiency mice RBC
12)
Dosage
After treating after losing blood before group number of animals g crude drug/kg loses blood
Blank group 16-7.32 ± 0.81 5.74 ± 0.61 6.84 ± 0.75
▲
Common process 14 18.0 6.98 ± 0.93 5.83 ± 0.79 7.63 ± 0.88
▲
Technology A low dosage 15 9.0 7.15 ± 1.01 6.26 ± 0.68 7.59 ± 0.66
▲
Technology A high dose 16 18.0 6.96 ± 0.68 5.43 ± 0.54 7.49 ± 0.51
▲
Technology B low dosage 15 9.0 7.03 ± 0.87 5.57 ± 0.53 7.32 ± 0.56
▲
Technology B high dose 14 18.0 7.12 ± 0.67 5.42 ± 0.68 7.45 ± 0.58
▲
1.2.2 influence to the white mice swimming time
Get white mice, difference gastric infusion, continuous 7 days, every day 1 time. fasting is 12 hours before the last administration, freely drinks water.After the last administration 60 minutes,, be put in the tank (depth of water 25cm, 20 ± 0.5 ℃ of water temperatures) every Mus tail heavy burden 2g paperclip.Calculate animal from the time (second) that the beginning nostril submerged that falls into water can not emerge in 10 seconds, as mice swimming time index.The result shows that the high low dose group of WUJI BAIFENG concentrated pill technology A, technology B all can obviously prolong the swimming time of mice, but the common process group can not prolong the swimming time of mice, and the effect of technology A, technology B all is better than the common process group.Concrete outcome sees Table 3.
Table 3 WUJI BAIFENG concentrated pills etc. are to the influence of white mice swimming time
The group number of animals dosage (swimming time (S) of g crude drug/kg)
Blank group 15-387.40 ± 194.67
Common process 14 18.0 403.07 ± 240.23
Technology A low dosage 10 9.0 657.76 ± 253.75
▲ ☆ ★
Technology A high dose 13 18.0 714.90 ± 187.06
▲ ▲ ☆ ☆ ★ ★
Technology B low dosage 14 9.0 632.74 ± 213.35
▲ ☆ ★
Technology B high dose 12 18.0 684.09 ± 166.60
▲ ▲ ☆ ☆ ★ ★
Compare with common process concentrated pill group,
★P＜0.05,
★ ★P＜0.01 time with
1.2.3 influence to white mice normal pressure anoxia enduring
Get white mice, gastric infusion respectively, continuous 5 days, mice was put in the 125ml wide mouthed bottle in 60 minutes after 1 administration every day, seal timing immediately, record death time of animal (second).The result shows WUJI BAIFENG concentrated pill technology A, technology B, equal energy significant prolongation white mice normobaric hypoxia death time of common process group, and wherein the effect of technology B high dose is the most obvious, and its effect is better than the common process group.Concrete outcome sees Table 4.
Table 4 WUJI BAIFENG concentrated pills etc. are to the influence of mice normal pressure hypoxia endurance time
(the g crude drug/Kg) hypoxia endurance time (S) prolongs percentage rate (%) to group number of animals dosage
Blank group 16-634.07 ± 102.47
Common process 16 18.0 803.06 ± 123.10 12.66
A technology low 16 9.0 836.50 ± 127.13
▲13.19
A technology is high by 16 18.0 863.40 ± 153.96
▲13.61
B technology low 16 9.0 860.51 ± 137.13
▲13.57
B technology is high by 16 18.0 988.44 ± 154.06
▲ ▲ ☆ ★15.58
1.2.4 influence to the reduction of caused by cyclophosphamide murine interleukin
Get mice, the outer cyclophosphamide model group that adds of conventional grouping after elder generation surveys the normal total white blood cells of peripheral blood before the administration, is irritated stomach medicine or normal saline respectively, continuous 7 days by group.After the administration the 4th day, except that the blank group, all the other equal intraperitoneal injection of cyclophosphamide 100mg/kg continued to irritate stomach medicine or normal saline again, repeated to check and examine the peripheral blood leucocyte sum behind the injection cyclophosphamide on the the 4th, 7 day respectively.The result show cyclophosphamide can make murine interleukin (WBC) obviously reduce (with give before the cyclophosphamide and with the blank group relatively, be P＜0.01=, WUJI BAIFENG concentrated pill technology A, technology B and common process are low to caused by cyclophosphamide murine interleukin sum, and tangible castering action is all arranged; Wherein the effect of technology A high dose is the most obvious, and its effect obviously is better than the common process group.The results are shown in Table 5.
The effect (* 10 that table 5 WUJI BAIFENG concentrated pill etc. reduce caused by cyclophosphamide pocket knife WBC
9)
Group number of animals dosage gives the ring phosphinylidyne for the ring phosphinylidyne for ring phosphorus
Before g crude drug/kg amide behind the amine behind 4 days amine 7 days
Blank group 14-5.7 ± 1.1 5.8 ± 1.4 5.9 ± 1.5
Cyclophosphamide model group 14-5.7 ± 2.1 2.9 ± 0.4 3.5 ± 0.4
Common process 16 18.0 5.8 ± 1.1 2.3 ± 0.4 4.8 ± 0.6
※
A technology low 14 9.0 5.7 ± 2.0 3.6 ± 0.3
※4.4 ± 0.3
※
A technology is high by 14 18.0 6.1 ± and 1.2 4.3 ± 0.4
※ ※ ★ ☆6.6 ± 0.5
※ ※ ★ ☆
B technology low 16 9.0 5.9 ± 1.4 3.1 ± 0.2 4.5 ± 0.9
※
B technology is high by 13 18.0 6.0 ± and 1.4 3.8 ± 0.4
※5.2 ± 0.5
※
Compare with the cyclophosphamide model group,
※P＜0.05,
※ ※P＜0.01.Down together.
1.2.5 to caused by cyclophosphamide mouse thymus coefficient, the influence of spleen index and adrenal gland's coefficient: grouping and medication are equal to 1.2.4, animal is put to death at injection cyclophosphamide the 7th day and after getting blood, get thymus, spleen and adrenal gland weigh, calculate the thymus coefficient, spleen index and adrenal gland's coefficient, the result shows that cyclophosphamide can make the thymus coefficient of mice, the last gland coefficient of spleen index and adrenal gland obviously reduces (with the comparison of blank group, be P＜0.01=, WUJI BAIFENG concentrated pill technology A, technology B and common process etc. are to caused by cyclophosphamide mouse thymus coefficient, the reduction of spleen index and adrenal gland's coefficient etc. does not all have obviously influence.The results are shown in Table 6.
The influence (mg/g) that table 6 WUJI BAIFENG concentrated pill etc. reduce caused by cyclophosphamide mouse thymus coefficient, spleen index and adrenal gland's coefficient
Group animal dosage thymus coefficient spleen index adrenal gland coefficient
Number (the g crude drug/kg)
Blank group 14-2.97 ± 0.54 3.32 ± 0.85 0.45 ± 0.12
Cyclophosphamide model group 14-1.85 ± 0.43 2.31 ± 0.81 0.30 ± 0.09
Common process 16 18.0 1.57 ± 0.44 2.33 ± 0.43 0.49 ± 0.86
A technology low 14 9.0 1.91 ± 0.47 2.30 ± 0.40 0.30 ± 0.11
A technology is high by 14 18.0 1.68 ± and 0.73 2.24 ± 0.51 0.35 ± 0.10
B technology low 16 9.0 2.11 ± 0.75 2.49 ± 0.65 0.38 ± 0.13
B technology is high by 13 18.0 2.02 ± and 0.69 2.59 ± 1.05 0.31 ± 0.09
1.2.6 influence to the mice bleeding time
Get white mice, administration is the same, successive administration 7 days, and after the last administration 1 hour, with the mice 3mm that docks, treat that blood flows out voluntarily to pick up counting, inhale the liquid 1 time of dehematizing every 30s with filter paper, stop naturally until hemorrhage, calculate and respectively organize the bleeding time.The result shows that WUJI BAIFENG concentrated pill technology A, technology B and common process etc. all can obviously shorten the normal mouse bleeding time, the effect no significant difference between each preparation.Concrete outcome sees Table 7.
Table 7 WUJI BAIFENG concentrated pill is to the influence (min) in mice bleeding time
Group number of animals dosage (the bleeding time suppression ratio (%) of g crude drug/kg)
Blank group 14-5.8 ± 1.4
Common process 14 18.0 4.1 ± 0.9
▲29.3
Technology A low dosage 12 9.0 4.4 ± 0.8
▲24.1
Technology A high dose 14 18.0 4.1 ± 1.2
▲29.3
Technology B low dosage 12 9.0 4.3 ± 0.9
▲25.8
Technology B high dose 14 18.0 4.2 ± 1.1
▲27.6
1.2.7 influence after the last administration 30 minutes to mice carbon clearance ability, tail vein injection india ink 0.1ml/10g body weight, the the 2nd, 8 minute with suction pipe (use in advance heparin solution moistening) in injection back, gets blood 20 μ l from the vena orbitalis posterior clump respectively, is dissolved in 2ml 0.1%Na
2CO
3Shake up in the solution, put 721 type spectrophotometers colorimetric under wavelength 640nm, measure optical density OD value, calculating K and a, the result shows that WUJI BAIFENG concentrated pill technology A, technology B and common process etc. all can obviously improve mice carbon clearance ability (P＜0.05), and prompting WUJI BAIFENG concentrated pill etc. has certain potentiation to immunologic function; The wherein effect of technology A high dose, technology B high dose the most obviously (P＜0.01), and its effect obviously is better than the common process group.The results are shown in Table 8.
Table 8 WUJI BAIFENG concentrated pills etc. are to mice carbon clearance function effect
Group dosage (the K a of g crude drug/kg)
Blank group-0.015 ± 0.012 5.25 ± 1.10
Common process 18.0 0.026 ± 0.012
▲6.38 ± 1.10
A technology low 9.0 0.033 ± 0.016
▲6.39 ± 0.53
A technology is high by 18.0 0.042 ± 0.013
▲ ▲ ★ ☆7.83 ± 1.10
B technology low 9.0 0.032 ± 0.009
▲6.83 ± 1.19
▲
B technology is high by 18.0 0.041 ± 0.012
▲ ▲ ★ ☆7.75 ± 1.10
▲ ▲ ★ ☆
1.2.8 the analgesic activity to mice is observed
Get white mice, the difference gastric infusion, continuous 5 days, every day 1 time, blank group and positive controls are given the normal saline with volume, continued gastric infusion (this timeliness matched group is given pethidine) on the 6th day, this 2ml/ of ice vinegar of pneumoretroperitoneum injection 0.6% in a hour only, the body active situation that clocks immediately and note observing mice, observe and the record mice produces the number of times of writhing response from giving glacial acetic acid mice to the time that produces writhing response and 15 minutes, the result shows WUJI BAIFENG concentrated pill technology A, technology B and common process group can not obviously prolong the incubation period that glacial acetic acid causes pain reaction, but technology A and technology B group all can significantly reduce the number of times that mice produces writhing response, wherein the effect of technology B high dose is the most obvious, and its effect is better than the common process group, and concrete outcome sees Table 9.
Table 9 WUJI BAIFENG concentrated pills etc. are to the observation of mice analgesic activity
(the g crude drug/kg) incubation period, (min) turned round the body number of times to group number of animals dosage
Blank group 14-5.22 ± 0.93 11.75 ± 4.58
Pethidine 14 0.8 9.03 ± 3.62
▲ ▲2.60 ± 2.03
▲ ▲ ☆ ☆ ★ ★
Common process 12 18.0 6.27 ± 1.73 8.78 ± 3.77
Technology A low dosage 13 9.0 5.50 ± 1.45 7.66 ± 3.68
▲
Technology A high dose 12 18.0 4.83 ± 2.17 7.45 ± 3.03
▲
Technology B low dosage 14 9.0 5.05 ± 2.83 7.78 ± 4.12
▲
Technology B high dose 13 18.0 5.25 ± 1.36 5.78 ± 2.63
▲ ▲ ☆ ★
1.2.9 influence to the isolated rat uterine smooth muscle
Regulate the electronics water-bath, keep constant temperature, the tyrode's solution in the Magnus' bath is 30ml, keeps 37 ± 0.5 ℃; Adjust tonotransducer, oxygen generator, BL-410 bio signal acquisition processing system etc.
The preparation of isolated uterine smooth muscle: get the female rats of 250-280g, pull cervical vertebra and put to death, cut the abdominal cavity immediately open, take out the uterus and insert and fill in the close phase liquid of cold history,, the uterus is cut into section about 2cm along the Uterus wall fractionation of fatty.
Two ends threading ligation is managed in the uterus, and an end the is on the ventilation hook, and the other end lies on the muscular tension transducer, the linkage record instrument.Aeration regulation speed is 1-2 bubble/s (not influence the autonomous motion degree of being that contracts that relaxes of uterine smooth muscle); Observe the normal uterus smooth muscle movement, wait to relax contract stable after, trace the normalized curve of one section smooth muscle, in bath, add the active situation that various medicinal liquid 0.3ml observe uterine smooth muscles then respectively, trace the curve that contracts that relaxes; Every kind of medicinal liquid is done 10 specimen, computer is analyzed after the administration 15 minutes uterine activity frequency automatically, the result shows that WUJI BAIFENG concentrated pill technology A, technology B and common process etc. all can obviously increase the activity upper frequency of normal rat isolated uterine smooth muscle, but the effect no significant difference between each preparation.Concrete outcome sees Table 10.
Table 10 WUJI BAIFENG concentrated pill is to the influence of isolated rat uterine smooth muscle
Group sample number dosage (frequency of g crude drug/ml) (inferior/min)
Blank group 10-1.77 ± 0.22
Common process 10 0.009 3.22 ± 0.27
▲
Technology A low dosage 10 0.0045 2.98 ± 0.40
▲
Technology A high dose 10 0.009 3.21 ± 0.55
▲
Technology B low dosage 10 0.0045 3.14 ± 0.45
▲
Technology B high dose 10 0.009 3.36 ± 0.58
▲
WUJI BAIFENG concentrated pill technology A, the result of pharmacological effect such as technology B and common process experimental study shows, under the identical situation of crude drug dosage, use technology A, technology B removes impurity a large amount of in the medical material, significantly reduce taking dose, make its reduce to original dosage 1/4 after, prepared concentrated pill is the same with common process, still has tangible tonifying blood and arresting bleeding, anti-stress, effects such as analgesia and raise immunity, the uterotonic ability of certain promotion is arranged, and compare with the WUJI BAIFENG concentrated pill of common process preparation, technology A is at the prolongation mice swimming time of anti-stress, the effect of aspects such as enhancing ring phosphamide induced mice WBC reduction and raise immunity is more obvious; Technology B is more obvious in the effect of aspects such as the prolongation mice swimming time of anti-stress and anoxia enduring and analgesic activity, raise immunity.
In addition, we have also done acute toxicity test (MTD method) research to the WUJI BAIFENG concentrated pill.Do not measure in the mouse stomach administration under the situation of LD50, irritate stomach three times in 24 hours, record mouse stomach A, two kinds of technology concentrated pills of B maximum dosage-feeding is 420g/kg, is equivalent to intend 1200 times of clinical people's consumption, is 4 times of the WUJI BAIFENG concentrated pill of common process preparation.
This test shows that two kinds of technology concentrated pills of A, B can significantly reduce the toxic and side effects of medicine.
Clinical research:
The WUJI BAIFENG concentrated pill mainly is made up of medicines such as Gallus Domesticus, Radix Ginseng, Rhizoma Dioscoreae, Radix Angelicae Sinensis, Radix Rehmanniaes Preparata, merit with benefiting qi and nourishing blood, adjusting meridian and stopping leukorrhea, mainly be applicable to women's deficiency of both QI and blood, cloudy insufficiency of essence and cause all diseases of gynecological, and some new usages have been emerged in large numbers in recent years, be used for diseases such as thrombocytopenia, aplastic anemia, male breast proliferative disease, nervous tinnitus as internal medicine, Andriatrics Dept. is used for seminal fluid not liquefaction, sexual impotence etc., uses to some extent at department of dermatologry, ophthalmology in addition.For observing its curative effect, we carry out following clinical research to technology A, B WUJI BAIFENG concentrated pill.
One, gynaecopathia
| Group | Typing | The example number | The produce effects example | Example takes a turn for the better | Invalid example | Total effective rate |
| Technology A group | Primary dysmenorrhea | ????58 | ????27 | ????18 | ????13 | ????77.60％ |
| Technology B group | Primary dysmenorrhea | ????62 | ????26 | ????18 | ????18 | ????71.0％ |
| The common process group | Primary dysmenorrhea | ????50 | ????20 | ????11 | ????19 | ????62.0％ |
| Technology A group | The supervention dysmenorrhea | ????51 | ????27 | ????14 | ????10 | ????80.4％ |
| Technology B group | The supervention dysmenorrhea | ????50 | ????28 | ????15 | ????7 | ????86.0％ |
| The common process group | The supervention dysmenorrhea | ????61 | ????33 | ????14 | ????14 | ????77.0％ |
| Technology A group | Dysfunctional uterine hemorrhage | ????68 | ????29 | ????34 | ????5 | ????92.6％ |
| Technology B group | Dysfunctional uterine hemorrhage | ????75 | ????35 | ????31 | ????9 | ????88.0％ |
| The common process group | Dysfunctional uterine hemorrhage | ????54 | ????25 | ????19 | ????10 | ????81.5％ |
| Technology A group | The deficiency syndrome leukorrheal diseases | ????60 | ????52 | ????4 | ????4 | ????93.3％ |
| Technology B group | The deficiency syndrome leukorrheal diseases | ????40 | ????30 | ????6 | ????4 | ????90.0％ |
| The common process group | The deficiency syndrome leukorrheal diseases | ????53 | ????31 | ????16 | ????6 | ????88.7％ |
Produce effects: transference cure, sign inspection all recover normal or alleviate
Take a turn for the better: symptom and sign all alleviate.
Invalid: treatment back symptom, sign is checked all and is improved.
Two, semen does not liquefy
| Group | The example number | Cure example | The produce effects example | Example takes a turn for the better | Invalid example | Total effective rate |
| Technology A group technology B group common process group | ????54 ????44 ????60 | ????24 ????21 ????25 | ????15 ????14 ????17 | ????12 ????6 ????7 | ???3 ???3 ???11 | ????94.4％ ????93.2％ ????88.7％ |
Cure: spouse's pregnancy.
Produce effects: though spouse end is conceived, the seminal fluid routine examination all occurs in the liquefying time 30min for continuous 2 times, and seminal fluid, the relevant index of prostatic fluid are all normal.
Effectively: treatment back seminal fluid liquefying time and viscosity obviously shorten before the treatment, and seminal fluid, the relevant index of prostatic fluid are clearly better.
Invalid: above index no change before and after the treatment.
Three, thrombocytopenia
| Group | Typing | The example number | Cure example | Effectively routine | Invalid example | Total effective rate |
| Technology A group | Idiopathic thrombocytopenic purpura | ??107 | ????85 | ????22 | ????0 | ??100.0％ |
| Technology B group | Idiopathic thrombocytopenic purpura | ??112 | ????82 | ????30 | ????0 | ??100.0％ |
| The common process group | Idiopathic thrombocytopenic purpura | ??94 | ????68 | ????26 | ????0 | ??100.0％ |
Cure: clinical symptom disappearance, the BPC counting, BT CT BT, CT, capillary fragility test recover normal.Follow up a case by regular visits to and do not have recurrence.
Effectively: clinical symptom disappearance, recurrence in 2 years, the each medication in recurrence back is still effective.
Invalid: the clinical indices no change.
By above clinical research being shown WUJI BAIFENG concentrated pill technology A, technology B, common process all have tangible curative effect to diseases such as gynecological, andropathys, and technology and the clinical total effective rate of technology A is more higher than technology B.
The specific embodiment:
Further specify the present invention by the following examples.
Embodiment 1:
1, prescription
With reference to the medical material and the usage ratio of 411 pages of the Pharmacopoeias of the People's Republic of China (2000 editions) " WUJI BAIFENG WAN " defined, prescription is decided to be Gallus Domesticus (removing feather claw and intestine) 2560g, Radix Ginseng 512g, Colla cornus cervi 512g, Concha Ostreae (forging) 192g, Radix Paeoniae Alba 512g, Radix Angelicae Sinensis 576g, Radix Glycyrrhizae 128g, Radix Astragali 128g, Carapax Trionycis (system) 256g, Rhizoma Cyperi (vinegar system) 512g, Radix Asparagi 256g, Ootheca Mantidis 192g, Radix Rehmanniae Preparata 1024g, Radix Rehmanniae 1024g, Rhizoma Chuanxiong 256g, Cornu Cervi Degelatinatum 192g, Radix Stellariae 104g, Semen Euryales (stir-fry) 256g, Rhizoma Dioscoreae 512g, Radix Salviae Miltiorrhizae 512g, make 1000g concentrated pill finished product.
1, preparation technology
The vegetable drug (Radix Angelicae Sinensis, Rhizoma Cyperi, Rhizoma Chuanxiong) that contains volatile oil is behind water vapour distillation volatile oil, with other plant medical material (Radix Ginseng, the Radix Astragali, the Radix Paeoniae Alba, Radix Asparagi, Radix Glycyrrhizae, Radix Rehmanniae, Radix Rehmanniae Preparata, Radix Stellariae, Radix Salviae Miltiorrhizae) respectively water be that solvent extracts aqueous soluble active constituent, extracting solution concentrates (pressure is 15-20kg) through NF membrane and gets concentrated solution (relative density 1.0-1.1), and it is standby to get dry powder through the about 25-36 of lyophilization hour again;
Animal drug (Gallus Domesticus, Colla cornus cervi, Concha Ostreae, Carapax Trionycis, Ootheca Mantidis, Cornu Cervi Degelatinatum) adds yellow wine (about 1: 1) and concocted evaporate to dryness about 24 hours, mix with Rhizoma Dioscoreae, Semen Euryales coarse powder, through lyophilization 32-36 hour, water content is controlled at below 3%, gets micropowder (granularity is 3-20 μ m) through the fluid energy mill micronizing again.Carrying volatile oil and 4% gumwater (volume ratio is 1: 25) are poured in the tissue mashing machine, high-speed stirred made volatile oil emulsion in 1 minute, 4% gelatin solution (with the arabic gum equivalent volumes) is mixed with emulsion, stirred 10 minutes, put in 37 ℃ of water-baths, constantly stir, it is an amount of to drip 10% acetum.Transferring pH value is 4, adds 200 milliliters of dilutions of acidify distilled water (pH value 4.5), constantly stirs and is cooled to 25 ℃, puts to be cooled in the ice bath below 10 ℃ again, adds 37% formaldehyde, and to transfer pH value with 20% sodium hydroxide be 8-9, continues stirring 1 hour.Leave standstill, the supernatant that inclines, microcapsule is washed till formaldehydeless flavor with distilled water, and cold drying promptly gets volatile oil microcapsule powder.With above-mentioned micropowder, dry powder, volatile oil microcapsule powder mix homogeneously, be pressed into ball with pellet press, dry, polishing promptly get the concentrated pill finished product.
Embodiment 2:
1, prescription
Identical with embodiment 1
2, preparation technology
The vegetable drug (Radix Angelicae Sinensis, Rhizoma Cyperi, Rhizoma Chuanxiong) that contains volatile oil is after vapor distillation extracts volatile oil, with other plant medical material (Radix Ginseng, the Radix Astragali, the Radix Paeoniae Alba, Radix Asparagi, Radix Glycyrrhizae, Radix Rehmanniae, Radix Rehmanniae Preparata, Radix Stellariae, Radix Salviae Miltiorrhizae) respectively water be that solvent extracts aqueous soluble active constituent, extracting solution concentrates (pressure is 15-20kg) through NF membrane and gets concentrated solution (relative density 1.0-1.1), and it is standby to get dry powder through the about 25-36 of lyophilization hour again; Animal drug (Gallus Domesticus, Colla cornus cervi, Concha Ostreae, Carapax Trionycis, Ootheca Mantidis, Cornu Cervi Degelatinatum) adds yellow wine (about 1: 1), airtight, the steaming and decocting thick paste is got in about 24 hours of steaming and decocting, mix with Rhizoma Dioscoreae, Semen Euryales coarse powder, through lyophilization 32-36 hour, water content was controlled at below 3%, got micropowder (granularity is 3-20 μ m) through the fluid energy mill micronizing again, above micropowder, dry powder blend is even, sprayed into volatile oil airtight about 4 hours, and used the pellet processing machine pill, dry, polishing promptly gets the concentrated pill finished product.
Embodiment 3:
1, prescription
Identical with embodiment 1
2, preparation technology
The vegetable drug (Radix Angelicae Sinensis, Rhizoma Cyperi, Rhizoma Chuanxiong) that contains volatile oil is after vapor distillation extracts volatile oil, reinstating 95% ethanol with other plant medical material (Radix Ginseng, the Radix Astragali, the Radix Paeoniae Alba, Radix Asparagi, Radix Glycyrrhizae, Radix Rehmanniae, Radix Rehmanniae Preparata, Radix Stellariae, Radix Salviae Miltiorrhizae) is that solvent extracts ester dissolubility effective ingredient, extracting solution concentrates (pressure is 15-20kg) through NF membrane and gets concentrated solution (relative density 1.0-1.1), and it is standby to get dry powder through the about 25-36 of lyophilization hour again;
Animal drug (Gallus Domesticus, Colla cornus cervi, Concha Ostreae, Carapax Trionycis, Ootheca Mantidis, Cornu Cervi Degelatinatum) adds yellow wine (about 1: 1), airtight, the steaming and decocting thick paste is got in about 24 hours of steaming and decocting, mix with Rhizoma Dioscoreae, Semen Euryales coarse powder, through lyophilization 32-36 hour, water content was controlled at below 3%, got micropowder (granularity is 3-20 μ m) through the fluid energy mill micronizing again, above micropowder, dry powder blend is even, sprayed into volatile oil airtight about 4 hours, and used the pellet processing machine pill, dry, polishing promptly gets the concentrated pill finished product.
Embodiment 4:
1, prescription
Identical with embodiment 1
2, preparation technology
The vegetable drug (Radix Angelicae Sinensis, Rhizoma Cyperi, Rhizoma Chuanxiong) that contains volatile oil is after vapor distillation extracts volatile oil, reinstating ethanol with other plant medical material (Radix Ginseng, the Radix Astragali, the Radix Paeoniae Alba, Radix Asparagi, Radix Glycyrrhizae, Radix Rehmanniae, Radix Rehmanniae Preparata, Radix Stellariae, Radix Salviae Miltiorrhizae) is that solvent extracts ester dissolubility effective ingredient, extracting solution concentrates (pressure is 15-20kg) through NF membrane and gets concentrated solution (relative density 1.0-1.1), and it is standby to get dry powder through the about 25-36 of lyophilization hour again;
Animal drug (Gallus Domesticus, Colla cornus cervi, Concha Ostreae, Carapax Trionycis, Ootheca Mantidis, Cornu Cervi Degelatinatum) adds yellow wine (about 1: 1), airtight, the steaming and decocting thick paste is got in about 24 hours of steaming and decocting, mix with Rhizoma Dioscoreae, Semen Euryales coarse powder, through lyophilization 32-36 hour, water content was controlled at below 3%, got micropowder (granularity is 3-20 μ m) through the fluid energy mill micronizing again, above micropowder, dry powder blend is even, sprayed into volatile oil airtight about 4 hours, and used the pellet processing machine pill, dry, polishing promptly gets the concentrated pill finished product.
Embodiment 5:
1, prescription
Medical material and usage ratio with reference to 411 pages of the Pharmacopoeias of the People's Republic of China (2000 editions) " WUJI BAIFENG WAN " defined, prescription is decided to be Gallus Domesticus (removing feather claw and intestine) 1920gg, Radix Ginseng 384g, Colla cornus cervi 384g, Concha Ostreae (forging) 144g, Radix Paeoniae Alba 384g, Radix Angelicae Sinensis 432g, Radix Glycyrrhizae 96g, Radix Astragali 96g, Carapax Trionycis (system) 192g, Rhizoma Cyperi (vinegar system) 384g, Radix Asparagi 192g, Ootheca Mantidis 144g, Radix Rehmanniae Preparata 768g, Radix Rehmanniae 768g, Rhizoma Chuanxiong 192g, Cornu Cervi Degelatinatum 144g, Radix Stellariae 78g, Semen Euryales (stir-fry) 192g, Rhizoma Dioscoreae 384g, Radix Salviae Miltiorrhizae 384g, makes 1000g concentrated pill finished product.
2, preparation technology
The vegetable drug (Radix Angelicae Sinensis, Rhizoma Cyperi, Rhizoma Chuanxiong) that contains volatile oil is behind water vapour distillation volatile oil, with other plant medical material (Radix Ginseng, the Radix Astragali, the Radix Paeoniae Alba, Radix Asparagi, Radix Glycyrrhizae, Radix Rehmanniae, Radix Rehmanniae Preparata, Radix Stellariae, Radix Salviae Miltiorrhizae) respectively water be that solvent extracts aqueous soluble active constituent, extracting solution concentrates (pressure is 15-20kg) through NF membrane and gets concentrated solution (relative density 1.0-1.1), and it is standby to get dry powder through the about 25-36 of lyophilization hour again;
Animal drug (Gallus Domesticus, Colla cornus cervi, Concha Ostreae, Carapax Trionycis, Ootheca Mantidis, Cornu Cervi Degelatinatum) adds yellow wine (about 1: 1) and concocted evaporate to dryness about 24 hours, mix with Rhizoma Dioscoreae, Semen Euryales coarse powder, through lyophilization 32-36 hour, water content is controlled at below 3%, gets micropowder (granularity is 3-20 μ m) through the fluid energy mill micronizing again.Carrying volatile oil and 4% gumwater (volume ratio is 1: 25) are poured in the tissue mashing machine, high-speed stirred made volatile oil emulsion in 1 minute, 4% gelatin solution (with the arabic gum equivalent volumes) is mixed with emulsion, stirred 10 minutes, put in 37 ℃ of water-baths, constantly stir, it is an amount of to drip 10% acetum.Transferring pH value is 4, adds 200 milliliters of dilutions of acidify distilled water (pH value 4.5), constantly stirs and is cooled to 25 ℃, puts to be cooled in the ice bath below 10 ℃ again, adds 37% formaldehyde, and to transfer pH value with 20% sodium hydroxide be 8-9, continues stirring 1 hour.Leave standstill, the supernatant that inclines, microcapsule is washed till formaldehydeless flavor with distilled water, and cold drying promptly gets volatile oil microcapsule powder.With above-mentioned micropowder, dry powder, volatile oil microcapsule powder mix homogeneously, be pressed into ball with pellet press, dry, polishing promptly get the concentrated pill finished product.
Claims (10)
1, a kind of new WUJI BAIFENG concentrated pill, it is characterized in that, by following Chinese medicine raw materials by weight proportion preparation, Gallus Domesticus 1920g-2560g, Radix Ginseng 384g-512g, Colla cornus cervi 384g-512g, Concha Ostreae 144g-192g, Radix Paeoniae Alba 384g-512g, Radix Angelicae Sinensis 432g-576g, Radix Glycyrrhizae 96g-128g, Radix Astragali 96g-128g, Carapax Trionycis 192g-256g, Rhizoma Cyperi 384g-512g, Radix Asparagi 192g-256g, Ootheca Mantidis 144g-192g, Radix Rehmanniae Preparata 768g-1024g, Radix Rehmanniae 768g-1024g, Rhizoma Chuanxiong 192g-256g, Cornu Cervi Degelatinatum 144g-192g, Radix Stellariae 78g-104g, Semen Euryales 192g-256g, Rhizoma Dioscoreae 384g-512g, Radix Salviae Miltiorrhizae 384g-512g, this Chinese medicine raw materials by weight proportion can prepare the pill of 1000g.
2, the WUJI BAIFENG concentrated pill of claim 1, it is characterized in that the weight proportion of its raw material of Chinese medicine is: Gallus Domesticus 1920g, Radix Ginseng 384g, Colla cornus cervi 384g, Concha Ostreae 144g, Radix Paeoniae Alba 384g, Radix Angelicae Sinensis 432g, Radix Glycyrrhizae 96g, Radix Astragali 96g, Carapax Trionycis 192g, Rhizoma Cyperi 384g, Radix Asparagi 192g, Ootheca Mantidis 144g, Radix Rehmanniae Preparata 768g, Radix Rehmanniae 768g, Rhizoma Chuanxiong 192g, Cornu Cervi Degelatinatum 144g, Radix Stellariae 78g, Semen Euryales 192g, Rhizoma Dioscoreae 384g, Radix Salviae Miltiorrhizae 384g.
3, the WUJI BAIFENG concentrated pill of claim 1, it is characterized in that the weight proportion of its raw material of Chinese medicine is: Gallus Domesticus 2560g, Radix Ginseng 512g, Colla cornus cervi 512g, Concha Ostreae 192g, Radix Paeoniae Alba 512g, Radix Angelicae Sinensis 576g, Radix Glycyrrhizae 128g, Radix Astragali 128g, Carapax Trionycis 256g, Rhizoma Cyperi 512g, Radix Asparagi 256g, Ootheca Mantidis 192g, Radix Rehmanniae Preparata 1024g, Radix Rehmanniae 1024g, Rhizoma Chuanxiong 256g, Cornu Cervi Degelatinatum 192g, Radix Stellariae 104g, Semen Euryales 256g, Rhizoma Dioscoreae 512g, Radix Salviae Miltiorrhizae 512g.
4, the preparation method of WUJI BAIFENG concentrated pill according to claim 1 is characterized in that, may further comprise the steps:
A, the vegetable drug Radix Angelicae Sinensis that contains volatile oil in will writing out a prescription, Rhizoma Cyperi, Rhizoma Chuanxiong be through water vapour distillation volatile oil, extracts the above-mentioned medical material behind the volatile oil of back, incorporates step b into and extract;
B, with Radix Ginseng, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Glycyrrhizae, the Radix Astragali, Rhizoma Cyperi, Radix Asparagi, Radix Rehmanniae Preparata, Radix Rehmanniae, Rhizoma Chuanxiong, Radix Stellariae, Radix Salviae Miltiorrhizae, water or alcohol extraction effective ingredient, gained extracting solution concentrate, concentrated solution gets dry powder through lyophilization;
C, will write out a prescription in Gallus Domesticus, Colla cornus cervi, Concha Ostreae, Carapax Trionycis, Ootheca Mantidis, Cornu Cervi Degelatinatum through the wine processing evaporate to dryness, mix with Rhizoma Dioscoreae, Semen Euryales coarse powder, after lyophilization, get micropowder through micronizing again;
D, with volatile oil, be the capsule material with natural macromolecular material, be prepared into microcapsule through the microencapsulation technology, washing is made the microcapsule powder after the cold drying, or volatile oil do not make dry microcapsule powder, and is stand-by;
E, dry powder, the micropowder of step c, the microcapsule powder mix homogeneously of steps d with step b, mixed powder, or with the dry powder of step b, the micropowder mix homogeneously of step c, the stand-by volatile oil of steps d is sprayed into, airtight a period of time, mixed powder;
F, the mixed powder of step e is pressed into ball with pellet press, dry, polishing promptly gets the concentrated pill finished product.
According to the preparation method of claim 4, it is characterized in that 5, natural macromolecular material described in the steps d is gelatin or arabic gum.
6, according to the preparation method of claim 4, it is characterized in that, is ethanol with alcohol extraction described in the step b.
According to the preparation method of claim 4, it is characterized in that 7, what concentrate employing described in the step b is the NF membrane concentration technique.
According to the preparation method of claim 4, it is characterized in that 8, the airtight a period of time described in the step e is 2-6 hour.
9, according to the preparation method of claim 4, it is characterized in that, the technology of microencapsulation described in the steps d adopts following technology, and carrying volatile oil and 4% gumwater are poured in the tissue mashing machine, high-speed stirred made volatile oil emulsion in 1 minute, 4% gelatin solution is mixed with emulsion, stirred 10 minutes, put in 37 ℃ of water-baths, constantly stir, it is an amount of to drip 10% acetum.Transferring pH value is 4, add 200 milliliters of dilutions of acidify distilled water, constantly stirring is cooled to 25 ℃, puts to be cooled in the ice bath below 10 ℃ again, adds 37% formaldehyde, and to transfer pH value with 20% sodium hydroxide be 8-9, continue to stir 1 hour, leave standstill, supernatant inclines, microcapsule is washed till formaldehydeless flavor with distilled water, and cold drying promptly gets volatile oil microcapsule powder.
According to the preparation method of claim 4, it is characterized in that 10, the micronizing described in the step c is through the fluid energy mill micronizing, the micropowder granularity of gained is 3-20 μ m.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101018729A CN1245196C (en) | 2003-10-22 | 2003-10-22 | Novel concentrated pill of wuji-Baifeng contg. black-bone chicken |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101018729A CN1245196C (en) | 2003-10-22 | 2003-10-22 | Novel concentrated pill of wuji-Baifeng contg. black-bone chicken |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1537613A true CN1537613A (en) | 2004-10-20 |
| CN1245196C CN1245196C (en) | 2006-03-15 |
Family
ID=34333119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101018729A Expired - Fee Related CN1245196C (en) | 2003-10-22 | 2003-10-22 | Novel concentrated pill of wuji-Baifeng contg. black-bone chicken |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1245196C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104013778A (en) * | 2014-06-24 | 2014-09-03 | 洛阳顺势药业有限公司 | Preparation process of traditional Chinese medicine fracture-setting qili pills |
| CN104491357A (en) * | 2014-12-28 | 2015-04-08 | 李宏良 | Traditional Chinese medicine composition as well as preparation method and application thereof |
| CN104740231A (en) * | 2013-12-27 | 2015-07-01 | 天津中新药业集团股份有限公司乐仁堂制药厂 | Pharmaceutical composition for treatment of qi-blood deficiency, irregular menstruation, metrorrhagia and leukorrheal diseases and preparation method thereof |
| CN105343477A (en) * | 2015-11-20 | 2016-02-24 | 广西天天乐药业股份有限公司 | Traditional Chinese medicinal composition for invigorating energy, nourishing blood, regulating menstruation and stopping bleeding, and preparation method thereof |
-
2003
- 2003-10-22 CN CNB2003101018729A patent/CN1245196C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740231A (en) * | 2013-12-27 | 2015-07-01 | 天津中新药业集团股份有限公司乐仁堂制药厂 | Pharmaceutical composition for treatment of qi-blood deficiency, irregular menstruation, metrorrhagia and leukorrheal diseases and preparation method thereof |
| CN104740231B (en) * | 2013-12-27 | 2018-09-04 | 天津中新药业集团股份有限公司乐仁堂制药厂 | A kind of pharmaceutical composition and preparation method thereof treated under qi-blood deficiency, irregular menstruation and uterine bleeding band |
| CN104013778A (en) * | 2014-06-24 | 2014-09-03 | 洛阳顺势药业有限公司 | Preparation process of traditional Chinese medicine fracture-setting qili pills |
| CN104013778B (en) * | 2014-06-24 | 2018-04-24 | 洛阳顺势药业有限公司 | The preparation process of seven lis of balls of Chinese medicine synthetism |
| CN104491357A (en) * | 2014-12-28 | 2015-04-08 | 李宏良 | Traditional Chinese medicine composition as well as preparation method and application thereof |
| CN105343477A (en) * | 2015-11-20 | 2016-02-24 | 广西天天乐药业股份有限公司 | Traditional Chinese medicinal composition for invigorating energy, nourishing blood, regulating menstruation and stopping bleeding, and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1245196C (en) | 2006-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1082904A (en) | Treat dermopathic pharmaceutical composition | |
| CN1698879A (en) | Product having sobering up and liver protecting functions and its preparation method and usage | |
| CN1872282A (en) | Active extractive of Foliumnerviliae, preparation method and application | |
| CN1879833A (en) | An wind-expelling ointment and method for preparing same | |
| CN1209128C (en) | Traditional Chinese medicine composition with function of treating dysmenorrhea and beautifying | |
| CN1883638A (en) | Compound medicine for treating depression and method for preparing same | |
| CN1239183C (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN1225252C (en) | Process for preparing composition comprising medicinal herb extract for preventing and curing arthritis and composition thereof | |
| CN1537613A (en) | Novel concentrated pill of wuji-Baifeng contg. black-bone chicken | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1194735C (en) | Chinese medicine for treating hyperplasia of mammary glands | |
| CN1535700A (en) | Blood-supplementing medicine composition | |
| CN1651036A (en) | Angelica root mistletoe granules and its preparation method | |
| CN1056298C (en) | External use medicine for treating soft tissue injury and its producing method | |
| CN1562113A (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN1316960C (en) | Compound mactra clam drip pill and its preparation method | |
| CN1660259A (en) | Chinese traditional medicine for treating imitable bowel syndrome and preparation method | |
| CN1336233A (en) | Hepatitis B treating medicine | |
| WO2020037853A1 (en) | Composition for promoting microcirculation and improving function of human body and preparation method therefor | |
| CN1602945A (en) | Rhinitis treating soft medicinal capsule and preparation process thereof | |
| CN1222305C (en) | Chinese medicine for treating liver-kidney insufficiency, qi and yin vacuity and its preparation method | |
| CN1216614C (en) | Pharmaceutical composition for delaying chronic renal failure | |
| CN1509729A (en) | Yanning adjuvant | |
| CN1714811A (en) | Radix bupleuri dripping pill and its preparing method | |
| CN1239199C (en) | Medicine for treating gastritis and peptic ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 1266 No. 330052 Nanchang Huiren Jiangxi economic and Technological Development Zone Avenue. Patentee after: JIANGXI HUIREN PHARMACEUTICAL CO.,LTD. Address before: 330043 No. 1189, Yingbin Avenue, Nanchang, Jiangxi Patentee before: Jiangxi Huiren Pharmaceutical Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060315 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |